Targeted Therapies for Cancer: ImmunoGen, Inc.

Site Map

ImmunoGen, Inc. develops targeted anticancer therapeutics. Our proprietary Tumor-Activated Prodrug (TAP) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies.

Genentech discloses Phase III "go" decision for trastuzumab-DM1 (T-DM1).

Learn more about this...

ImmunoGen’s Tumor-Activated Prodrug (TAP) technology can expand the potential of monoclonal, or manufactured, antibodies in the treatment of cancer.

See our EORTC posters ...

11/11/2008
ImmunoGen, Inc. Announces Webcast of Presentation at the Lazard Capital Markets Fifth Annual Healtcare Conference

11/10/2008
ImmunoGen, Inc. Appoints James J. O'Leary, MD, as Vice President and Chief Medical Officer

Read our releases...

built@zoomedia.com

Last updated November 11, 2008